Details of the Drug Combination

General Information of Drug Combination (ID: DCV6Q9M)

Drug Combination Name
DFN-15 Aminolevulinic Acid Hydrochloride
Indication
Disease Entry Status REF
Carcinoma Investigative [1]
Component Drugs DFN-15   DM3BF9B Aminolevulinic Acid Hydrochloride   DMWNHPC
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: RXF 393
Zero Interaction Potency (ZIP) Score: 1.28
Bliss Independence Score: 3.83
Loewe Additivity Score: 2.96
LHighest Single Agent (HSA) Score: 2.9

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of DFN-15
Disease Entry ICD 11 Status REF
Migraine 8A80 Phase 3 [2]
Indication(s) of Aminolevulinic Acid Hydrochloride
Disease Entry ICD 11 Status REF
Actinic keratosis EK90.0 Approved [3]
Aminolevulinic Acid Hydrochloride Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Protoporphyrinogen oxidase (PPOX) TTNFMS9 PPOX_HUMAN Modulator [4]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DCR6PBH OVCAR3 Investigative [5]
Adenocarcinoma DCR974N A549 Investigative [5]
Adenocarcinoma DCGIN10 HT29 Investigative [5]
Large cell lung carcinoma DC6KSYC NCI-H460 Investigative [5]
Malignant melanoma DCTVX8C LOX IMVI Investigative [5]
Prostate carcinoma DCJY69O PC-3 Investigative [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DrugCom(s)

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.